The miR-573/E2F3 axis might serve as a novel biomarker to predict the progression and prognosis of pancreatic cancer, as well as a potent therapeutic target in the treatment of pancreatic cancer. This evidence concerns the gene E2F3 and familial pancreatic carcinoma.